摘要
目的:观察复方青黛片、全反式维A酸(alltransretinoicacid,ATRA)与化疗交替治疗缓解后急性早幼粒细胞白血病(acutepromyelocyticleukemia,APL)临床疗效。方法:对初诊24例APL患者,先用复方青黛片或ATRA治疗达完全缓解,再用化疗与ATRA、复方青黛片序贯交替治疗,持续缓解3年以上者监测PML/RARα基因,再决定是否停药或继续治疗。结果:24例全部存活,复发率8.3%,未发现严重副作用。结论:复方青黛片、ATRA与化疗交替治疗APL疗效满意,副作用少。
Objective:To observe the clinical effect of compound qingdai tablets,all-trans retinoic acid(ATRA) and chemotherapy for the treatment of acute promyelocytic leukemia(APL) of complete remission.Methods:Twenty-four cases of newly diagnosed APL were induced to complete remission by using compound qingdai tablets or ATRA first,then treated alternatively with compound qingdai tablets,ATRA and chemotherapy.We monitored the PML/RARα fusion genes of the patients who maintained remission for 3 years and then decided whether to stop the therapy or continue.Results:All the cases survived.The relapse rate was 8.3% and the side effect was mild.Conclusions:The therapy of sequential use of compound qingdai tablets,ATRA and chemotherapy for treatment of APL of complete remission has the advantages of good results and mild side effects.
出处
《蚌埠医学院学报》
CAS
2005年第4期317-318,共2页
Journal of Bengbu Medical College
